Expressing treatment-associated changes

被引:2
作者
Chrubasik, S [1 ]
Conradt, C
Black, A
机构
[1] Univ Freiburg, Inst Forens Med, D-79104 Freiburg, Germany
[2] Univ Sydney, Herbal Med Res & Educ Ctr, Sydney, NSW 2006, Australia
[3] Heidelberg Univ, Dept Med Biometry, D-69120 Heidelberg, Germany
[4] Univ Bristol, Bristol Royal Infirm, Dept Anaesthesia, Bristol BS2 8HW, Avon, England
来源
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2005年 / 64卷 / 06期
关键词
outcome measures; pain; back; hip; knee;
D O I
10.1007/s00393-005-0696-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Osteoarthritis Research Society International is attempting to establish a consensus on outcome measures, so as to facilitate comparability between different clinical studies in this area of research. There are no general recommendations on how changes in outcome measure (effect size) should be expressed. We therefore used data from a recently published study to express change as: a) the mean of the change from baseline divided by the individual baseline, b) the median of the change from baseline divided by the individual baseline, c) the mean of the change from baseline divided by the SD of baseline and d) the median of change from baseline divided by the SD of baseline. The results show that the correlations between different ways of expressing effect sizes were poor and the perceived relative magnitudes of various effects depended on how they were expressed. Organisations aiming at consensus ought to recommend the way in which change ought to be expressed. Until they do, authors should justify their choice of expression, particularly if it critically influences their conclusion, and/or present their data as fully as possible on a website.
引用
收藏
页码:423 / 427
页数:5
相关论文
共 16 条
[1]  
Bellamy N, 1997, J RHEUMATOL, V24, P799
[2]  
BELLAMY N, 1988, J RHEUMATOL, V15, P1833
[3]  
Chrubasik S, 1999, EUR J ANAESTH, V16, P118
[4]   The quality of clinical trials with Harpagophytum procumbens [J].
Chrubasik, S ;
Conradt, C ;
Black, A .
PHYTOMEDICINE, 2003, 10 (6-7) :613-623
[5]   A randomized double-blind pilot study comparing Doloteffin® and Vioxx® in the treatment of low back pain [J].
Chrubasik, S ;
Model, A ;
Black, A ;
Pollak, S .
RHEUMATOLOGY, 2003, 42 (01) :141-148
[6]  
Chrubasik S, 1996, PHYTOMEDICINE, V3, P1, DOI 10.1016/S0944-7113(96)80003-1
[7]   Comparison of outcome measures during treatment with the proprietary Harpagophytum extract Doloteffin® in patients with pain in the lower back, knee or hip [J].
Chrubasik, S ;
Thanner, J ;
Künzel, O ;
Conradt, C ;
Black, A ;
Pollak, S .
PHYTOMEDICINE, 2002, 9 (03) :181-194
[8]   Potential economic impact of using a proprietary willow bark extract in outpatient treatment of low back pain:: An open non-randomized study [J].
Chrubasik, S ;
Künzel, O ;
Black, A ;
Conradt, C ;
Kerschbaumer, F .
PHYTOMEDICINE, 2001, 8 (04) :241-251
[9]   Treatment of low back pain exacerbations with willow bark extract: A randomized double-blind study [J].
Chrubasik, S ;
Eisenberg, E ;
Balan, E ;
Weinberger, T ;
Luzzati, R ;
Conradt, C .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (01) :9-14
[10]   Comparison of a disease-specific and a generic instrument for measuring health-related quality of life in ankylosing spondylitis [J].
Helliwell, PS ;
Marzo-Ortega, H ;
Tennant, A .
ARTHRITIS AND RHEUMATISM, 2002, 46 (11) :3098-3098